Indivior PLC (INDV.L)

1,514.00 -10.00 (-0.66%) At close: 04:35PM BST

Indivior PLC

10710 Midlothian Turnpike
Suite 125
North Chesterfield, VA 23235
United States
804 379 1090
https://www.indivior.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 1,164

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Mark Crossley	CEO & Executive Director	1.89M	N/A	N/A
Mr. Ryan Preblick	CFO & Executive Director	915.5k	N/A	N/A
Dr. Christian Heidbreder	Chief Scientific Officer	N/A	N/A	N/A
Mr. Jason Thompson	Vice President of Investor Relations	N/A	N/A	N/A
Ms. Cynthia Cetani	Chief Integrity & Compliance Officer	N/A	N/A	N/A
Mr. Jeffrey W. Burris	Chief Legal Officer	N/A	N/A	1972
Mr. Jon Fogle	Chief Human Resources Officer	N/A	N/A	N/A
Mr. Richard Simkin	Chief Commercial Officer	N/A	N/A	N/A
Mr. Hillel West	Chief Manufacturing & Supply Officer	N/A	N/A	N/A
Mr. Vishal Kalia	SVP of US Treatment Access, Support Programs & Business Insights and Chief Impact & Strategy Officer	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Corporate governance

Indivior PLC’s ISS governance QualityScore as of 1 April 2024 is 8. The pillar scores are Audit: 10; Board: 4; Shareholder rights: 1; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.